Aging therapies: the most powerful economic productivity lever of the twenty-first century

While governments invest billions in education and digital innovation to boost productivity, they overlook the single largest drag on employment: declining health in midlife and beyond. Chronic diseases generate direct costs of $1.1 trillion in the United States (5.8% of GDP), but when indirect losses in economic productivity are included, the figure rises to $3.7 trillion—nearly 20% of total GDP. Advocates for aging research argue that targeting the biological causes of aging is an inevitable economic strategy, not merely a healthcare imperative. Unlike gradual changes that financial systems can absorb over decades, emerging therapeutic advances point toward possible discontinuities: increases in life expectancy that could materialize within years rather than generations. For the longevity-conscious reader, the case is clear: governments should allocate funding and create public-private partnerships in aging biology just as they did with antibiotics and vaccines in the twentieth century.